108,129 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Bought by Advantage Alpha Capital Partners LP

Advantage Alpha Capital Partners LP purchased a new stake in Puma Biotechnology, Inc. (NASDAQ:PBYI) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 108,129 shares of the biopharmaceutical company’s stock, valued at approximately $276,000. Advantage Alpha Capital Partners LP owned 0.22% of Puma Biotechnology at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in PBYI. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Puma Biotechnology during the 3rd quarter valued at about $44,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Puma Biotechnology by 3.9% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 368,455 shares of the biopharmaceutical company’s stock valued at $940,000 after purchasing an additional 13,941 shares in the last quarter. Prospera Financial Services Inc grew its stake in shares of Puma Biotechnology by 12.9% in the 3rd quarter. Prospera Financial Services Inc now owns 168,885 shares of the biopharmaceutical company’s stock valued at $431,000 after purchasing an additional 19,315 shares during the period. Royce & Associates LP grew its stake in shares of Puma Biotechnology by 71.8% in the 3rd quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 8,427 shares during the period. Finally, Victory Capital Management Inc. raised its holdings in shares of Puma Biotechnology by 111.9% in the 3rd quarter. Victory Capital Management Inc. now owns 35,097 shares of the biopharmaceutical company’s stock worth $89,000 after buying an additional 18,532 shares in the last quarter. Institutional investors and hedge funds own 61.29% of the company’s stock.

Puma Biotechnology Stock Performance

NASDAQ:PBYI opened at $3.14 on Wednesday. The stock has a market capitalization of $154.14 million, a P/E ratio of 6.54 and a beta of 1.09. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46. Puma Biotechnology, Inc. has a 1 year low of $2.22 and a 1 year high of $7.73. The firm has a 50 day moving average of $2.78 and a 200-day moving average of $3.15.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.10. The firm had revenue of $80.50 million during the quarter, compared to the consensus estimate of $71.32 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. During the same quarter in the previous year, the company posted $0.12 EPS. As a group, sell-side analysts anticipate that Puma Biotechnology, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Puma Biotechnology in a research note on Wednesday, November 20th. StockNews.com lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Friday, November 22nd.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.